Synopsis:
Namita Thapar-backed Emcure Pharmaceuticals Ltd reported a resilient Q1FY26 performance, with net profit rising 9.1 percent QoQ and 40.5 percent YoY to Rs. 215 crore, aided by strong growth across both domestic and international markets.
A pharma stock backed by Namita Thapar slipped sharply during Thursday’s session amid broader market volatility and sector-specific tariff headwinds, even as the company delivered strong bottom-line growth for the June quarter.
Emcure Pharmaceuticals Ltd, with a market cap of Rs. 26,531.17 crore, opened at Rs. 1,405 against the previous close of Rs. 1,422.30, and touched an intraday low of Rs. 1,370, marking a 3.68 percent decline.
What’s the News?
Quarter-on-Quarter, Emcure’s revenue remained largely steady at Rs. 2,101 crore, down 0.7 percent from Rs. 2,116 crore in Q4FY25. However, operating profit increased 3.7 percent to Rs. 417 crore from Rs. 402 crore, while profit before tax rose 11.5 percent to Rs. 291 crore from Rs. 261 crore.
Net profit jumped 9.1 percent to Rs. 215 crore, compared to Rs. 197 crore in the previous quarter. Operating margin improved to 20 percent from 19 percent, and EBITDA margin expanded to 19.23 percent from 18.43 percent.
Year-on-Year, the company delivered strong growth. Revenue rose 15.7 percent from Rs. 1,815 crore in Q1FY25 to Rs. 2,101 crore in Q1FY26. Operating profit surged 24.1 percent from Rs. 336 crore to Rs. 417 crore, and PBT climbed 40.6 percent from Rs. 207 crore to Rs. 291 crore.
Net profit increased by a robust 40.5 percent, up from Rs. 153 crore to Rs. 215 crore. EBITDA margin rose to 19.23 percent, compared to 18.53 percent in the same quarter last year.
Also Read: Vijay Kedia stock in focus after reporting 171% YoY increase in net profit
Management Commentary
Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said,
“We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast growing metabolic segment.
We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins.”
Operational Highlights
The company’s domestic business revenue stood at Rs. 995 crore, up 9.4 percent YoY and 7.1 percent QoQ, led by strong growth across key therapies and new initiatives in dermatology and OTC. Emcure further strengthened its India presence by expanding its partnership with Sanofi to now include oral anti-diabetic products alongside its cardiovascular portfolio.
International business revenue came in at Rs. 1,106 crore, rising 22.1 percent YoY but down 6.9 percent QoQ, with broad-based growth across geographies. The Rest of World segment maintained momentum with a 42 percent YoY growth, while Canada grew 16.4 percent driven by new product launches and higher market share. Europe rose 12.8 percent, also supported by early traction in new launches.
About the Company
Emcure Pharmaceuticals Ltd. is a Pune-based pharmaceutical major known for its research-led innovation and focus on differentiated therapies across therapeutic areas. Founded in 1981, Emcure ranks as the 12th largest Indian pharma company by domestic sales (MAT June 2024) and has a global footprint in over 70 countries, including strong presence in Europe and Canada.
Written By Manan Gangwar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
